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Abstract
Background: To increase the uptake of key clinical recommendations for non-surgical management of knee
osteoarthritis (OA) and improve patient outcomes, we developed a new model of service delivery (PARTNER model)
and an intervention to implement the model in the Australian primary care setting. We will evaluate the
effectiveness and cost-effectiveness of this model compared to usual general practice care.
Methods: We will conduct a mixed-methods study, including a two-arm, cluster randomised controlled trial, with
quantitative, qualitative and economic evaluations. We will recruit 44 general practices and 572 patients with knee OA in
urban and regional practices in Victoria and New South Wales. The interventions will target both general practitioners (GPs)
and their patients at the practice level. Practices will be randomised at a 1:1 ratio. Patients will be recruited if they are aged
≥45 years and have experienced knee pain ≥4/10 on a numerical rating scale for more than three months. Outcomes are
self-reported, patient-level validated measures with the primary outcomes being change in pain and function at
12 months. Secondary outcomes will be assessed at 6 and 12 months. The implementation intervention will support and
provide education to intervention group GPs to deliver effective management for patients with knee OA using tailored
online training and electronic medical record support. Participants with knee OA will have an initial GP visit to confirm their
diagnosis and receive management according to GP intervention or control group allocation. As part of the intervention
group GP management, participants with knee OA will be referred to a centralised multidisciplinary service: the PARTNER
Care Support Team (CST). The CST will be trained in behaviour change support and evidence-based knee OA
management. They will work with patients to develop a collaborative action plan focussed on key self-management
behaviours, and communicate with the patients’ GPs. Patients receiving care by intervention group GPs will receive tailored
OA educational materials, a leg muscle strengthening program, and access to a weight-loss program as appropriate and
agreed. GPs in the control group will receive no additional training and their patients will receive usual care.
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Discussion: This project aims to address a major evidence-to-practice gap in primary care management of OA by
evaluating a new service delivery model implemented with an intervention targeting GP practice behaviours to improve
the health of people with knee OA.
Trial Registration: Australian New Zealand Clinical Trials Registry: ACTRN12617001595303, date of registration 1/12/2017.
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Background
Arthritis and musculoskeletal conditions are more
prevalent in Australia than any other National Health
Priority area, including cancer, diabetes and obesity [1].
Osteoarthritis (OA) in particular is a leading cause of
pain, disability and early exit from the workforce in
Australia [2], with the knee commonly affected. Arthritis
leads to a substantial loss of income [3] (with a resultant
increase in welfare dependency) [4] and reduction in
taxation revenue, and a significantly increased risk of
falling into poverty [5].
Current care of people with OA in Australia is incon-
sistent with clinical guidelines, with 57% of people not
receiving appropriate care according to evidence-based
quality indicators [6]. As a result, 68% of Australians
with arthritis report “doing badly” or “fairly badly” with
respect to how their lives are affected by arthritis [7].
Knee OA in Australia is mostly managed in general
medical practice. A recent systematic review has
highlighted that general practitioners (GPs) are ham-
pered in their treatment of this chronic condition by
lack of knowledge of non-surgical management options,
and limited access to services that support the key rec-
ommended options such as lifestyle and behavioural
changes [8]. To address this gap, GPs and other health
professionals [9–11] have called for new models for OA
primary care that provide clear clinical pathways and
support networks to allow multi-disciplinary input and
lifestyle counselling for ongoing self-management of
OA. This trial aims to address a major evidence-to-
practice gap in primary care management of OA by
evaluating a new service delivery model implemented
with an intervention targeting GP practice behaviours to
improve the health of people with knee OA. Importantly,
the model of service delivery aligns with key recommen-
dations of established models of care in Australia [10]
and will provide important policy-relevant data to sup-
port implementation and scalability of these models.
Current clinical guidelines emphasise non-surgical
treatments, coupled with appropriate pharmacologic
care, as the cornerstone of OA management [12, 13]. In
particular, education and advice, exercise and physical
activity, and weight management are the gold standards.
Benefits of exercise were well-established in a 2015
Cochrane Review [14] with effect sizes higher than, or
comparable to, those of simple analgesics and oral non-
steroidal anti-inflammatories [15]. Patients with knee
OA often report preferring exercise over drug treat-
ments [16], due to a lower risk profile. For those who
are overweight or obese, weight loss is critical to im-
proving overall health and joint symptoms [17]. Meta-
analysis suggests patients should reduce body weight by
at least 5% to gain improvement in pain and function
[18], while a large RCT [19] has provided further evi-
dence of the benefits of ~ 10% weight loss in OA popu-
lations, particularly when diet is combined with exercise.
Analysis of Australian BEACH data [20] from 487,000
GP consultations for OA found rates of drug prescrip-
tion were much higher than rates of lifestyle manage-
ment (79 vs 21/100 knee OA contacts). Most referrals
were directly to orthopaedic surgeons (68%) with few to
physiotherapists (18%). Among people with hip/knee
OA referred for orthopaedic management at a major
Australian tertiary hospital, 80% felt they had not been
sufficiently educated about OA and 33% had not en-
gaged in any core non-drug conservative treatment [21].
A meta-analysis assessing OA care [22] found that qual-
ity indicator pass rates were suboptimal particularly for
non-drug, non-surgical treatment, demonstrating that
this is a worldwide problem. Such gaps in care are highly
relevant as poorer access to adequate information about
OA, poorer perceived quality of care and poorer per-
ceived GP knowledge about treatment options are asso-
ciated with worse patient outcomes [7].
Undertaking regular exercise and losing weight is difficult
for many people with knee OA and requires long-term be-
haviour change, coupled with appropriate support. A scop-
ing review highlighted many barriers to undertaking
exercise, including lack of knowledge and/or incorrect be-
liefs about capabilities and consequences [23]. Similarly,
89% of obese patients with knee OA consider lack of motiv-
ation to be their greatest barrier to weight loss [24]. Effect-
ive communication and support from health professionals
are vital for self-belief and sustained motivation [25]. How-
ever, many clinicians typically practice within a biomedical
framework that inadequately considers psychosocial factors
that are important in disease control [26]. In addition, time
constraints in consultations and a lack of knowledge, skills
and confidence in behavioural counselling are reported as
barriers to optimal OA care delivery by GPs [8].
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The need for new, effective primary care models was
identified as the research priority most likely to alleviate
Australian OA burden at the 2012 Australian OA
Summit [27]. It was also identified in a White Paper by
Arthritis Australia following stakeholder consultation.
[28] There is also a wealth of evidence to support the
system-level benefits of the development and evaluation
of models of care and their models of service delivery
[29], including a broad acceptance of this approach in
Australia [30]. As such we have performed extensive
work to develop a new model of service delivery: the
PARTNER model, and have designed an implementation
plan for delivering the model in the current Australian
primary care context. PARTNER is underpinned by the
Chronic Care model [31], evidence-based clinical prac-
tice guidelines [12, 13], and informed by broad stake-
holder input (consumers, GPs, physiotherapists,
rheumatologists, nurses, behaviour change experts, pol-
icy makers, health insurers and consumer advocates)
and the knowledge and experience of the Osteoarthritis
Healthy Weight For Life Program (OAHWFL) [32]. The
implementation plan was designed using the ‘Behaviour
Change Wheel’ and informed by the Theoretical
Domains Framework [33]. The implementation plan tar-
gets GPs via GP professional development modules and
provision of a desktop EMR support tool, and the PART-
NER model targets their patients who are referred to a
centralised, remotely-delivered, multi-disciplinary Care
Support Team (CST) for proven exercise, weight loss
and pain management interventions. Further details on
the theory underpinning the development of the PART-
NER model of service delivery and the implementation
plan will be presented in a separate paper.
The aim of this project is to implement the PARTNER
model for people with knee OA in an Australian primary
care setting and to evaluate the effectiveness and cost-
effectiveness of the PARTNER model compared with
usual care. We hypothesise the PARTNER model will be
superior. We will also conduct a process evaluation to
assess success of the implementation plan, PARTNER
model fidelity, identify contextual influences on scalabil-
ity and sustainability and identify cost considerations for
scaling up the GP-level intervention and CST service
throughout Australian primary care.
Methods/ design
Trial design
The PARTNER trial is a mixed-methods study including
a two-arm, pragmatic, cluster randomised controlled
trial (RCT), a health economic analysis and nested quali-
tative evaluations. The primary endpoint for analysis is
at 12 months. The protocol conforms to the Standard
Protocol Items Recommendations for Interventional
Trials (SPIRIT) 2013 Statement for developing clinical
trial protocols [34]. The trial was prospectively registered
on the Australian New Zealand Clinical Trials Registry
(ACTRN12617001595303), and the World Health Or-
ganisation Universal Trial Number is U1111–1197-4809.
Study population and setting
We will recruit 44 general practices with a minimum of
two GP participants per practice, and 572 of their
patients.
General practices and GPs
will be recruited from metropolitan and regional areas
of Victoria and New South Wales, Australia, through
our GP Research Networks. Practice elibility criteria in-
clude: i) at least two registered GPs at a practice agree to
be involved; ii) use of a general practice clinical desktop
system compatible with the electronic desktop IT sup-
port tool being used for the study (cdmNet); iii) current
public liability insurance; iv) consent to be randomised,
and v) did not participate in the pilot study. GPs are eli-
gible if they: i) work in a participating practice; ii) are
registered with professional indemnity insurance; iii) are
willing to undertake the study as per the protocol, and
iv) currently treat patients with knee OA.
Patients
Potential patients will be identified from the general
practice’s patient database, and the inclusion criteria are
based on the National Institute for Health and Care Ex-
cellence (OARSI) Guidelines for Osteoarthritis Care and
Management in Adults [35]. Eligible patient participants
will be i) aged 45 years or older; ii) report activity-
related knee pain for more than 3 months; iii) report
knee pain over the past week as greater than 3 on an 11-
point numerical rating scale (NRS, with terminal de-
scriptors of “no pain” and “worst possible pain”) at
screening, and iv) either be a patient of a GP participant
or agree to see a GP participant in the same practice. Pa-
tients are not eligible to participate if they cannot pro-
vide informed consent in English, have limited mobility
requiring the use of a wheelchair or scooter or are non-
ambulatory, have had or are booked in for knee replace-
ment surgery in the knee they are seeking treatment for,
are terminally ill, have rheumatoid arthritis or gout or
other severe inflammatory condition, or are undergoing
treatment for serious medical/psychiatric conditions that
would preclude participation (e.g. cancer treatment).
Trial procedures
Figure 1 outlines the trial phases. General practices, GPs
and patients will be screened and consented as outlined
below. GPs will complete surveys at baseline and after
all their participants have had an initial consultation. Pa-
tients will complete assessments at baseline, 6 months
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and 12 months, and after their initial GP consultation.
An additional survey will be sent to all patients at
3 months to assess participation in study components,
and monthly surveys to collect health service usage data
for economic evaluation. Surveys will be sent and com-
pleted via the Research Electronic Data Capture tool
(REDCap) [36] online database software, or if necessary
via hard copy surveys sent and returned by mail.
Recruitment
General practices and GPs will be recruited through the
Victorian Primary Care Practice-Based Research
Network (VicReN, based at the University of Melbourne,
Victoria, Australia) and the New South Wales (NSW)
Primary Health Care Research Network (PHReNet,
based at University of NSW Sydney, Australia). At least
one phone call and practice visit will be undertaken to
provide a detailed description of the study, screen the
practices and GPs for inclusion, gain informed consent,
and to familiarise GPs regarding the required training in
study methods, the professional development obligations
if allocated to the intervention group (see GP interven-
tion below), and the support provided by the study
team.
Patients will be recruited from the practice’s patient
database. Practice staff will identify patients ≥45 years
Fig. 1 Flow diagram of the study. The recruitment of patients will occur after the practices and GPs have been recruited and randomised, and
after GPs have completed their baseline assessment. Patients will only be considered to be enrolled in the trial after they have submitted both
their informed consent forms and completed the baseline assessment
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who are patients of the enrolled GPs. The list will be
randomised for the mail out, and before the practice is
advised of its group allocation GPs will have the oppor-
tunity to exclude any patients they know do not meet
the inclusion criteria. The practice will send out letters
inviting participation on behalf of the researchers, using
the practice’s usual method of communication with their
patients: post or email. Invitation letters will be sent out
in batches until the required number of patients from
that practice are recruited. The exclusion list will be
checked by the PARTNER Study GP coordinators prior
to the letters being sent to ensure all eligible participants
in each batch are contacted. Interested patients will
complete an online screening questionnaire. Those who
pass online screening will be contacted by trial staff for
further phone-based confirmation of eligibility and to
discuss details of study participation. Eligible patients
will be mailed a participant information statement and
consent form for participation in the study, and separate
consent form authorising the study to access their
complete Medicare Benefits Schedule (MBS) and
Pharmaceutical Benefits Scheme (PBS) data for the eco-
nomic evaluation.
All recruited general practices, GPs and patients will
provide written informed consent. This study involves
limited disclosure for patients so as to limit pre-conceived
ideas as to the superiority of one service delivery method.
The information and consent documents provide infor-
mation about the purposes, potential risks and processes
of the study, but do not include specific details of the
intervention. Consented patients will receive an email link
to, or mailed hard copy of, the baseline survey for comple-
tion. Once the baseline survey has been completed and
checked by the research team the participant is deemed to
have entered the study. The 12-month patient interven-
tion commences at this time (Fig. 1).
Randomisation and allocation concealment
General practices will be randomised, rather than indi-
vidual GPs or patients, as the intervention involves
changes at the practice level. Once GP recruitment at
the site is completed, general practices will be randomly
allocated to either the intervention or usual care control
group at a 1:1 ratio, and by random permuted blocks of
sizes 8, 10 and 12. Stratification will be by practice size
(< 4 GPs, ≥4 GPs) and location (metropolitan, regional/
rural), based on the Australian Statistical Geography
Standard (ASGS) Remoteness Structure (2011) [37].
Metropolitan areas will correspond to the ASGS major
cities classification (RA1), while regional/rural will be a
combination of the inner regional (RA2), outer regional
(RA3), remote (RA4) and very remote classifications
(RA5). Offsite computer-generated randomisation will
be conducted by the study statistician. Opaque, sealed
envelopes will be used to conceal allocation and are kept
in a locked location.
Patient participants are considered ‘assessors’ in this
study as all primary outcomes are self-reported. Thus, as
participants are blinded to group allocation the trial is
also ‘assessor’ blinded. Statistical analyses will be under-
taken by blinded statisticians. Staff of VicReN and
PHReNet assigned to assist each practice will be blinded
until the point of practice allocation. Research staff in-
volved in patient screening will be blinded until after
they have made the eligibility decision. It is not possible
to blind the GPs to group allocation, however, they are
requested not to discuss the study allocations with their
patients.
Intervention
The PARTNER model includes management by both the
GP and the new CST service to improve patient out-
comes (Fig. 2). The implementation intervention aims to
facilitate the GPs’ role in the PARTNER model. Patient
participants will all have an initial visit to their GP for
confirmation of an OA diagnosis and a knee OA focused
consultation as their GP sees fit. Patient participants of
GPs allocated to the intervention group will receive care
described in the PARTNER model. Delivery of the
PARTNER model depends on GPs receiving the imple-
mentation intervention (GP intervention) and the pa-
tient receiving care for 12 months by the CST service.
These two components are described below. GPs in the
control group will receive no intervention and their pa-
tients will not have access to the CST. After the initial
GP consultation, control patient participants will con-
tinue to receive ‘usual GP care’ for their knee OA.
GP intervention
According to the PARTNER model, GP management in-
cludes confirmation of OA diagnosis, providing advice
on the importance of exercise and weight management,
reviewing their pain medications, referring to the PART-
NER CST and if appropriate preparing a Chronic
Disease Management Plan. The GPs allocated to the
intervention group will be required to undertake a range
of “core” professional development activities related to
best practice management of knee OA to facilitate their
understanding of the PARTNER model before seeing pa-
tients in the study. All professional development activ-
ities can be completed online and are self-paced. The
topics are based on the NICE Clinical Guidelines for the
management of OA [12], and include:
a. GP self-audit activity: A self-audit and feedback ac-
tivity will guide GPs to reflect on their management
of recent patients with OA and self-identify any
areas for improvement. Part 1 of the audit is a
Hunter et al. BMC Musculoskeletal Disorders  (2018) 19:132 Page 5 of 16
required element of the study and should be com-
pleted before the GP completes any other profes-
sional development activities. GPs will be asked to
identify and describe five recent consultations
where they diagnosed and managed a person pre-
senting with chronic knee pain. The GPs will be
asked to answer 20 questions on the priorities for
best practice diagnosis and management of knee
OA. The questions were selected and modified for
the audit from three sources by an expert panel
[38–40]. Based on their score, the GPs will then re-
ceive feedback consisting of short evidence sum-
maries that address potential areas to improve best
practice care.
Part 2 of the audit is optional and completed after
all their patients have completed their involvement
with the study. GPs are asked to repeat the 20
questions from Part 1.
They are provided with their scores from both parts
of the audit and given the opportunity to revisit the
priority components of care for knee OA.
Completion of both parts of the audit allows GPs to
claim Quality Improvement and Continuing
Professional Development (QI&CPD) category 1
points from the Royal Australian College of General
Practitioners (RACGP).
b. Knee osteoarthritis in general practice’ online
learning module: An on-line professional develop-
ment module on evidence-based knee OA diagnosis
and treatment developed in collaboration with the
RACGP. The approximately 1-h package covers
current best-practice recommendations for non-
surgical management of OA. The module is located
on the RACGP website as part of their QI&CPD
program [41]. Completion of it confers one RACGP
QI&CPD point (category 2).
c. ‘Introduction to the PARTNER Study: GPs will be
asked to view a short video on the PARTNER study,
which outlines the aims of the study and will briefly
introduce the PARTNER model (Fig. 2). It gives an
overview of the intervention processes and tasks
that need to be completed by both the GP and the
patients enrolled in the study, including study aims,
patient recruitment, study tasks for patients and
GPs, governance requirements and reporting
serious adverse events and study contact details.
In addition to the professional development program,
GPs are provided with desktop OA management tools
via cdmNet software. cdmNet is a network of online
computing services and infrastructure designed to help
GPs and other healthcare providers manage people with
chronic diseases, and facilitate referral to other health
professionals [42]. cdmNET includes decision support
features to prompt GPs in evidence-based OA consult-
ation activities, an OA care plan, a mechanism for refer-
ral to the CST and HWFL, and PARTNER-specific
educational resources which can be printed out for the
patient. All general practices and GPs allocated to the
intervention group will receive training in the cdmNet
software, and free copies of the software if required.
Optional skills and capacity building modules are also
available online for GPs who would like further training
on specific topics. Topics include: how lifestyle changes
Fig. 2 PARTNER model of service delivery
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can improve symptoms and improve function; different
options for non-surgical management of OA; how to
have conversations with patients about OA, weight loss
and exercise; brief advice incorporating a motivational
interviewing approach; and the importance of optimism
and positive expectations on outcomes. Further reading
and links to other OA resources and research will also
be provided for interested GPs.
The PARTNER care support team
The PARTNER CST is a centralised, multidisciplinary
team of health professionals trained in best-practice OA
management, health coaching and behavioural change.
The CST will support patients to manage their knee OA
and will help the GP facilitate additional healthcare ser-
vices, if required. After referral, a member of the CST
will contact the participant patient to discuss the CST
service, the different OA management options, help the
patient prioritise their needs and agree goals.
The CST will be comprised of a multidisciplinary al-
lied health team with nine members from a range of
professions including physiotherapy, exercise physiology
and occupational therapy. The CST will be trained in be-
haviour change methodology and health coaching by our
partner, HealthChange Australia. The CST training will
comprise 2 workshops (total 3 days) on the Health-
Change Australia™ methodology [43]. Between the 2
workshops the CST members will each be required to
undertake two practice phone calls to four patients, and
to self-appraise their skills for two of these patients. The
calls will be recorded, and one pair of calls from each
member sent to HealthChange Australia for review and
group feedback. Additional webinar training sessions for
the CST will be held on best practice management of
knee OA, the PARTNER study procedures and the soft-
ware used for the study.
The CST will deliver the intervention remotely via
phone, video call, email, post and/or SMS contact, as
per individual patient preference. The patient’s first
contact session with the CST will occur at approxi-
mately one month from patient enrolment, contingent
on GP availability. During the first contact session a
member of the CST will undertake a biopsychosocial
assessment of the patient and provide further educa-
tion about OA and different management options. A
tailored care plan aligned to the patient’s individual
health needs will be developed with a particular focus
on the study’s priority areas of weight loss, exercise
and physical activity. Secondary intervention options
for other issues are also available for patients to
undertake (see Secondary interventions below). Patient
priorities and goals should evolve over the course of
the intervention. The CST intervention will occur in
two phases (Fig. 1):
1. Phase 1 – first 18 weeks. The patient will be
contacted once per fortnight on average, or as agreed
with the patient. The CST will provide ongoing self-
management advice and support, to address the goals
and activities of their tailored care plan.
2. Phase 2–6 month maintenance period (or until the
end of the 12-month intervention period). Patients
will be encouraged and supported to develop strat-
egies to self-manage their OA. They will be con-
tacted monthly, or as agreed, to monitor their
progress and address any new or ongoing issues as
required. Patients can still be re-referred to their
GP or other allied health professionals if an escal-
ation of care is required. However, patients cannot
elect to participate in the HWFL weight-loss pro-
gram during this phase.
The CST will provide updates to the GPs on the pro-
gress of their referred patients via cdmNET at three time
points (after initial consultation, after 18 weeks and at the
end of the patient’s involvement with the CST), or on re-
quest by the GP. The reports will detail any strategies and
actions agreed with the patient, and their progress to date.
The CST will refer the patient back to their GP if they re-
quire a medication review, or if they have any other med-
ical condition that affects participation in the trial or an
escalation of care. If the situation is urgent the CST mem-
ber will ring the GP to discuss. If the situation is routine
the CST will correspond with the GP via cdmNET.
Priority interventions
All patients allocated to the Intervention group will be
offered the ‘priority’ interventions. These interventions
are recommended by the NICE Clinical Guidelines for
the management of all people with knee OA [12]. While
patients are strongly encouraged to undertake all the
priority interventions recommended by the CST, it is ul-
timately their decision on the interventions to under-
take. The priority interventions include:
a. Education: provision of OA educational resources
compiled by the PARTNER team and our partner
organisations, as well as links to Arthritis Australia’s
OA consumer website ‘myjointpain.org.au’ and the
‘painHEALTH’ website, [44, 45] a brochure
introducing the CST and a range of other
information sources and other self-monitoring tools.
b. Muscle strengthening program: A physiotherapist-
developed home exercise program for leg strength-
ening which includes the common exercises used to
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strengthen the thigh and buttock muscles, and pro-
vides tips for progressing the exercises and how to
stay motivated with an exercise program. Patients
will be provided with exercise resistance bands to
assist them to progress. This program will be pro-
vided by the CST.
c. Physical activity plan: the CST will help the patient
with strategies to increase their incidental and
general physical activity levels.
d. Weight loss advice and support: If the patient has a
BMI ≥27 kg/m2, the patient will be offered the
option of participating in the remotely-delivered
“Healthy Weight for Life®” weight loss program
which has been shown to be effective in people with
OA [32]. The program is an 18-week, three-phase
approach provided by PRIMA Healthcare, and in-
volves a very low-calorie diet (KicStart™), a portion-
controlled eating system, an exercise program, and
educational resources on a healthy diet and lifestyle.
After the 18-weeks patients will be referred back to
the PARTNER CST, and if required can continue to
be provided with weight loss advice until the end of
the intervention period. Patients who do not wish
to undertake the HWFL program, or are not eligible
for the program, will continue to be managed by
the CST throughout the whole intervention period,
as described above. They will be offered all other
relevant components of the intervention.
e. Medication review: Patients will be offered a review
of their current OA medications. This should be
undertaken by the GP at the initial consultation,
however their medications will continue to be
discussed by the CST, using an algorithm
previously developed for Arthritis Australia’s
myjointpain.org.au website. Patients will be
encouraged to speak to their GP or local
pharmacist if they require a medication review.
Secondary interventions, online management tools and
community run services
Patients may also be directed to one or more online
tools, or community run services for the management of
different aspects of their OA. The online tools have been
developed by experts in their field. Referral to these on-
line services will be offered if the patient meets the pre-
determined criteria for stepping up care and/or has
identified as their priority for action. These components
are optional for the patient and include:
a. Advice on mobility aides or secondary therapies
such as walking sticks, orthoses, or heat pads.
b. Pain coping skills training: an online 8-week Cogni-
tive Behavioural Therapy (CBT) program for pain
coping skills training which has been shown to be
effective in knee OA [46]. The pain coping skills
training program is an online program comprised of
eight modules that provide interactive training in
cognitive or behavioural pain coping skills. It is be-
ing provided free of charge for patients in the study.
c. Depression - This Way Up: an online CBT program
for education and treatment of anxiety and
depression [47]. It will be offered to intervention
patients in the study free of charge [48].
d. Insomnia and sleep – SHUTi: the online CBT
program “SHUTi” was designed to help people with
insomnia identify and change thoughts or
behaviours that influence sleep patterns [49]. The
course is offered in Australia through the Black Dog
Institute [50]. The completion of this course is
optional and would be at an additional cost.
e. Community-based services and facilities: Depending
on the patient’s preference for service delivery (e.g.
group vs individual), they may be directed to
services or facilities run by community groups or
other commercial entities, such as exercise classes,
public gyms or other sporting organisations. These
options would be at an additional cost.
f. Work productivity: If patients self-report a decrease
in their work productivity due to their knee OA
they will be given the option of being referred to a
vocational counsellor in their area. This option
would be at an additional cost.
Usual care
Patients in the control group will be asked to visit their
GP for an initial consultation. GPs will not refer their
patients to the CST, but will manage the patient’s OA in
their usual manner (usual care). Management of the pa-
tient’s OA is purely at the discretion of the GP. GPs will
only receive a brief introduction to the study. GPs may
refer to any third-party provider, which may incur add-
itional out-of-pocket expenses. Patients may attend these
services at their own discretion and cost. Once the GP
in this group has completed their involvement in the
study (i.e. all of their patients have had their final follow-
up assessment), they will be offered the opportunity to
undertake the training and professional development op-
portunities offered to the GPs in the intervention group.
The exception would be the provision of the cdmNet
software and training.
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Outcome measures
Table 1 summarises the primary and secondary out-
come measures. The outcomes include patient-level
validated measures recommended for OA by the
Osteoarthritis Research Society International (OARSI)
and International Consortium for Health Outcomes
(ICHOM) [51, 52], or have been used in other similar
trials. Patients will be asked to nominate their most
symptomatic knee (provided it has not undergone
arthroplasty), which will be considered their “study
knee” for the duration of the trial. Primary and sec-
ondary outcome data will be collected at baseline, 6
and 12 months after enrolment and are self-reported
unless otherwise specified in Table 1. 24-month
follow-ups will also be conducted. The two primary
outcomes are:
1. Change in average knee pain at 12 months: overall
average pain over the past week self-reported via an
11-point NRS with terminal descriptors of ‘no pain’
(score 0) and ‘worst pain possible’ (score 10).
2. Change in physical function of the knee at
12 months: knee function will be measured using
the function in daily living subscale of the Knee
injury and Osteoarthritis Outcome Score (KOOS)
[53]. The KOOS questionnaire measures symptoms
and functional limitations associated with knee OA
using patient-reported outcome measures. The
questionnaire consists of five subscales; pain, other
symptoms, function in daily living (ADL), function
in sport and recreation (Sport/Rec) and knee-
related Quality of Life (QOL), measured using
Likert responses scored from 0 to 4. The questions
pertain to the previous seven days. The KOOS is a
widely used disease-specific instrument whose valid-
ity, reliability and responsiveness have been demon-
strated in a range of OA studies [54].
Our secondary outcome measures are:
1. Change in knee pain at 6 months: overall average
pain over the past week will be self-reported via a
NRS and the pain sub-scale of the KOOS (as de-
scribed above).
2. Change in physical function of the knee at
6 months: will be measured using the Function
(Activities of Daily Living) subscale of the
KOOS.
Table 1 Summary of primary and secondary data collected from study patient participants to determine intervention effectiveness
Outcome Measurement tool
Primary Outcome Measures
Knee pain 11-point numerical scale
Knee function Knee injury and Osteoarthritis Outcome Score (KOOS) -
function in daily living subscale
Secondary Outcome Measures
Knee pain KOOS pain subscale
Knee function KOOS - function in daily living subscale
Knee OA symptoms KOOS - other symptoms subscale
Knee function with sport and recreation KOOS - function with sport and recreation subscale
Knee quality of life KOOS - knee-related Quality of Life subscale
Weight and BMI (calculated) Self-report
Health-related quality of life Assessment of Quality of Life (AQoL-8D)
Depression Patient Health Questionnaire (PHQ 9)
Sleep impairment PROMIS adult Sleep-Related Impairment Short Form 8a
Fatigue PROMIS Fatigue Short Form 8a
Global rating of change 7-point numerical rating scale
Satisfaction, overall with treatment 7-point numerical rating scale
Satisfaction with change in symptoms 7-point numerical rating scale
Work productivity Work Productivity and Activity Impairment Questionnaire:
Osteoarthritis of the Knee V2.0 (WPAI:OA)
Health Care Expenditure Medicare Benefits Schedule (MBS) and Pharmaceutical
Benefits Scheme (PBS) data.
Economic evaluation of the cost-effectiveness of the intervention Based on the Assessment of Quality of Life (AQoL-8D)
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3. Change in other OA symptoms of the knee at 6 and
12 months will be measured using the Symptoms
subscale of the KOOS.
4. Change in QoL at 6 and 12 months will be
measured using the Quality of Life subscale of the
KOOS.
5. Change in function of the study knee during sport
and recreational activities at 6 and 12 months will
be measured using the Function (sports and
recreational activities) subscale of the KOOS.
6. Change in weight and BMI at 6 and 12 months.
BMI will be calculated using baseline height data.
Patients will be asked to use the same set of scales
to measure their weight for all time points. It is
recommended that these outcomes are assessed for
all OA clinical trials that target symptom-modifying
interventions [51].
7. Change in health-related QoL at 6 and 12 months
will be assessed via the Assessment of Quality of Life
(AQoL-8D) [55]. The AQoL-8D is a health-related
multi-attribute utility quality of life instrument, ini-
tially designed for use in economic evaluation stud-
ies. This instrument has 35 items in 8 separately
scored dimensions; independent living, relation-
ships, mental health, coping, pain, senses, self-worth
and happiness. The questions pertain to the previ-
ous 7 days.
8. Change in depression (mood) at 6 and 12 months
will be measured using the Patient Health
Questionnaire (PHQ9) [56]. The PHQ9 is a multi-
purpose instrument for screening, diagnosing, mon-
itoring and measuring the severity of depression. It
is used widely for identifying depression in chronic
conditions including OA. There are nine questions
scored on a 4-point scale (0 = not at all, 3 = nearly
every day). The questions pertain to the previous
14 days. Score responses are normal, mild, moder-
ate, moderately severe, severe and very severe. Any
patient with a classification of severe or above, or
presents with thoughts of self-harm, will be referred
back to their GP for their follow-up.
9. Sleep impairment at 6 and 12 months will be
measured using the Patient-Reported Outcomes
Measurement Information System (PROMIS™) adult
Sleep-Related Impairment Short Form 8a (patient
self-report) [57]. The tool consists of eight questions
that ask patients to rate their perceptions of alert-
ness, sleepiness, and tiredness during usual waking
hours, and the perceived functional impairments
during wakefulness associated with sleep problems
or impaired alertness. The questions pertain to the
previous seven days. Five response options are used
ranging in value from 1 (not to all) to 5 (very
much). The total raw score is calculated by the sum
of values of the response to each question (min 8,
max 40).
10. Change in fatigue at 6 and 12 months will be
measured using the PROMIS™ Short Form 8a
(patient self-report) [57]. The tool consists of eight
questions that ask patients to rate their perceptions
of fatigue symptoms ranging from mild subjective
feelings of tiredness to an overwhelming, debilitat-
ing, and sustained sense of exhaustion that likely
decreases one’s ability to execute daily activities and
function normally in family or social roles. Fatigue
is divided into the experience of fatigue (frequency,
duration, and intensity) and the impact of fatigue
on physical, mental, and social activities over a 7-
day period. Five response options are used ranging
in value from 1 (not to all) to 5 (very much). The
total raw score is calculated by the sum of values of
the response to each question (min 8, max 40).
11. Change in patient’s global rating of change in knee
OA at 6 and 12 months. Patients will be asked to
rate their overall perceived change in OA on a 7-
point scale ranging from “much worse” to “much
better”.
12. Satisfaction with treatment will be measured at 6
and 12 months on a 7-point scale ranging from “ex-
tremely unsatisfied” to “extremely satisfied”.(47)
13. Satisfaction with change in knee OA symptoms
(outcome) will be measured at 6 and 12 months on
a 7-point scale ranging from “extremely unsatisfied”
to “extremely satisfied” [58].
14. Change in lost productivity at 6 and 12 months will
be measured using the Work Productivity and
Activity Impairment Questionnaire: Osteoarthritis
of the Knee V2.0 (WPAI:OA) [59]. This instrument
measures the time away from work because of knee
OA and the effect of knee OA on productivity while
at work. The questions pertain to the previous
seven days.
15. Healthcare expenditure will be extracted from the
MBS and PBS data. Medicare data includes
information on medical visits and procedures, and
the associated costs and PBS data includes
information on prescription medicines filled at
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pharmacies. We will seek patients’ consent to access
their MBS and PBS data from the Australian
Government Department of Human Services (DHS,
approval no. MI7185). A structured health diary
will be used to collect other health services on the
use of services not included in MBS and PBS data
such as hospitalisation, non MBS-funded allied
health service use and over the counter
medications.
16. Economic evaluation of the cost effectiveness of the
intervention.
Additional measures
A range of additional measures (using both quantitative
and qualitative methods) will be collected for the pur-
poses of answering questions about the potential medi-
ation of treatment effects, referrals to other health
professionals and utilisation of other services, barriers
and facilitators to implementing the intervention, fidelity
of the training provided, long-term implementation
needs and economic analyses (Table 2). These analyses
will not be used to measure treatment effectiveness. Spe-
cific instruments used include:
a) Change in physical activity levels measured with the
Physical Activity Scale for the Elderly (PASE), at 6
and 12 months. The PASE is a 10-item question-
naire used to measure both the frequency and type
of recreational and occupational physical activity
undertaken by participants over the previous seven
days. Higher scores indicate greater levels of phys-
ical activity. The PASE was developed and validated
in samples of older adults ≥ 55 years of age and has
been used in many OA clinical trials [60].
b) Change in patient’s fear of movement and activity
measured with the Brief Fear of Movement Scale for
Osteoarthritis [61] at 6 and 12 months. The
questionnaire consists of six statements and
patients are asked to indicate how much they agree
or disagree with each statement. The four response
options range in value from 1 (strongly disagree) to
4 (strongly agree).
c) Change in patient’s pain catastrophising measured
with the Pain Catastrophizing Scale (PCS) [62] at 6
and 12 months. The instrument is widely used in
both clinical practice and research. The PCS is a
13-item instrument designed to quantify an individ-
ual’s pain experience and measure catastrophic
thinking related to pain. Patients will be asked to in-
dicate the degree to which they have the above
thoughts and feelings when they are experiencing
pain on a five point response scale ranging from 0
(not at all) to 4 (all the time). A total score is ob-
tained (0–52), and can also be divided into three
subscales that assess rumination, magnification and
helplessness.
Table 2 Summary of other data collected from study patient participants. Baseline survey collected at 0 months
Outcome Measurement tool Collected at
Mediator measures
Physical activity levels Physical Activity Scale for the Elderly (PASE) 0, 6 and 12 months
Fear of movement Brief Fear of Movement Scale (BFMS) 0, 6 and 12 months
Pain catastrophising Pain Catastrophising Scale (PCS) 0, 6 and 12 months
Pain coping skills Coping Strategies Questionnaire (CSQ) 0, 6 and 12 months
Ability to manage their condition Effective Consumer Scale (EC17) 0, 6 and 12 months
Perception of their OA Brief Illness Perception Questionnaire (B-IPQ) 0, 6 and 12 months
Arthritis self-efficacy Arthritis Self-Efficacy Scale (ASES) 0, 6 and 12 months
Other patient collected data
Post GP visit questionnaire Custom questionnaire Immediately after GP visit,
~ 2–6 weeks
Quality of OA care delivered during study Osteoarthritis Quality Care Indicator (OA-QI) 6 and 12 months
Patient activation or self-management attitudes Patient Activation Measure (PAM) 0 months
Treatment expectation Custom questionnaire 0 and 6 months
Willingness for surgery Custom questionnaire 0, 6 and 12 months
Participation in study components Custom questionnaire 0, 6 and 12 months
Intervention adherence questions Custom questionnaire 6 and 12 months
Adverse events Custom questionnaire 0, 6 and 12 months
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d) Change in patient’s pain coping skills at 6 and
12 months. This is measured using the Coping
Strategies Questionnaire (CSQ) [63] at 6 and
12 months. The CSQ can be used to measure how
often a patient uses six cognitive and behavioural
pain coping strategies to manage pain (diverting
attention, re-interpreting pain sensations, coping
self-statements, ignoring pain sensations, praying
and hoping, and increasing activity level). We will
use the coping attempts subscale comprising 17
questions. Items are measured on a 7-point Likert
scale (where 0 = never uses coping skills and 7 = al-
ways uses coping skills). Higher scores indicate
greater coping skills. Based on prior factor analyses
of this instrument [63] participant’s responses will
be converted to scores on the Coping Attempts fac-
tor of the CSQ. The CSQ has demonstrated sensi-
tivity to change from treatment in samples of
people with chronic pain as well as good internal
consistency and construct validity.
e) Change in patient’s ability to manage their
condition at 6 and 12 months: The Effective
Consumer Scale (EC17) will be used to determine
how effective people are at dealing with their
chronic condition and how well they make
decisions about their health care [64]. This 17-item
instrument has been validated in patients with arth-
ritis diseases and comprises five domains looking at
i) use of health information, ii) clarifying personal
priorities, iii) communicating with others iv) negoti-
ating roles and taking control, and v) deciding to
take action. It is measured on a five-point scale with
responses ranging from 0 (never) to 4 (always).
f ) Change in patient’s perceptions of their OA at 6
and 12 months. The Brief Illness Perception
Questionnaire (B-IPQ) [65] will be used to assess
changes in the patient’s perception of their
condition. The B-IPQ is an eight-item instrument
that measures the cognitive perceptions with re-
spect to a condition on an ordinal scale (0–10). The
areas examined are: i) consequences, ii) timeline, iii)
personal control, iv) treatment control, v) identity
for describing the condition and symptoms, vi) co-
herence, and vii) concern and emotions. The max-
imal score is 80, with higher scores reflecting more
negative perceptions.
g) Change in patient self-efficacy will be measured
using the short form eight item Arthritis Self-
Efficacy Scale (ASES) at 6 and 12 months [66]. It
will be administered at baseline, 6 and 12 months.
The 8-item short form is a validated version of the
original version, and was designed to take less time
for trial participants to complete. The participant is
asked how certain they are that they can do the fol-
lowing tasks at the present time. The instrument in-
cludes two items on pain, four items on other
symptoms, and two items that relate to preventing
pain and fatigue from interfering with daily activ-
ities. Each question is ranked on a scale of 1–10
ranging from 1 “very uncertain” to 10 “very certain”.
The total score is the mean of the eight items.
Economic evaluation
An economic evaluation will be conducted from the
health care system perspective. We will assess cost-
effectiveness of the intervention analysing a range of
outcomes including incremental cost per extra person
with a clinically significant improvement in pain (mea-
sured as 1.8 point reduction on the 0–10 pain score)
and per quality-adjusted life years (QALYs) gained for
the intervention group compared to the control group at
12 months. QALYs will be calculated based on utility
scores using the AQoL-8D at baseline, and 12 months.
We will compare the differences in health care usage
and utility gains on the AQoL-8D over 12 months be-
tween intervention and control groups (adjusting for any
difference in the baseline values between the groups).
We will also compare changes in productivity lost from
baseline to 12 months between the intervention and
control groups.
Data collection, management and analysis
Data collection and management
Study data will be primarily collected and managed
using the REDCap tool hosted at the University of Syd-
ney. REDCap is a secure, web-based application de-
signed to support data capture for research studies [36].
Where hard copy questionnaires have been completed,
they will be transcribed into REDCap by the research
staff and the original scanned and uploaded to REDCap.
We will collect MBS and PBS data from the Australian
Commonwealth Department of Human Services (DHS)
at the completion of the trial. Hard copy consent forms
will be scanned and stored on a University of Sydney or
University of Melbourne server, and the original form
locked in a filing cabinet until it is sent to the DHS at
the end of the trial. Study data, including MBS and PBS
consent forms, will be retained for 15 years after which
time it will be destroyed.
Statistical methods
Sample size estimation, power and justification
Primary endpoints are at the patient level and are de-
fined as changes in knee pain and function at 12 months.
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We wish to detect an effect size of 0.30 (moderate) [67].
Our sample size accounts for clustering effects due to
people treated within the same GP practice. Assuming a
minimum of 2 GPs per practice, 13 patients per GP
practice recruited, with a coefficient of variation in prac-
tice size of 0.5, an intra-cluster correlation of 0.05 and
up to 20% attrition of both GPs and patients, a total of
44 general practices and 572 patients will be required to
detect the effect size with 80% power (two-sided signifi-
cance level of 5%).
Statistical analysis
GP practices and individual participants will be analysed
according to their randomised group, using intention-to-
treat. Those practices that fail to recruit any patients or
withdraw from the study prior to collecting data from
any patients will be excluded from the analysis [68]. De-
scriptive statistics at the participant and GP practice
level will be presented to allow comparison of treatment
groups at baseline. Analyses will be conducted at the
participant level. For continuous outcome measures, dif-
ferences in mean change (baseline minus follow-up) will
be compared between groups using generalised estimat-
ing equations (GEEs) to account for within-practice cor-
relation with exchangeable correlation, robust standard
errors, and adjusting for the baseline value of the out-
come variable and stratification variables. For binary
outcomes, GEEs will be fitted using a logit link function
assuming an exchangeable correlation structure and ro-
bust variance estimation, adjusting for stratification vari-
ables, with results presented as odds ratios. To aid
interpretation, risk differences will also be calculated
using marginal probabilities [69]. Multiple imputation
will be applied to missing participant-level data from GP
practices which do not withdraw from the study before
data collection and that recruit at least one patient [70].
An independent Data Safety and Monitoring Board
(DSMB) will meet periodically to monitor the quality of
trial data and the safety of patients. The DSMB may rec-
ommend continuing the trial or modifying the trial, or
stopping the trial early. A recommendation to stop the
trial may only be made to protect the safety of trial par-
ticipants if there is clear evidence of a clinically import-
ant harmful effect.
Timelines
The study application for funding was approved by the
National Health and Medical Research Council
(NHMRC) in May 2016, and funding commenced in
January 2017. A pilot study to inform the main trial was
undertaken from May to December 2017. Recruitment
and training of the PARTNER CST occurred between
May and October 2017. Recruitment for the RCT com-
menced in March 2018 and is due for completion in
February 2019. The trial is due for completion in March
2020 after the 12 months data collection is complete.
Adverse events
The risks for participants involved in this study are min-
imal. There will be multiple mechanisms for identifying
serious adverse events (SAEs) that occur during the trial.
Firstly, if the CST become aware of any SAE, they will
inform the patient’s GP for follow-up and will advise the
Chief Investigator and Trial Coordinator as soon as pos-
sible. Secondly, if a patient cannot be contacted over a
four week period or at the end of the trial, the trial staff
will contact the GP to confirm if the participant is still
alive or has had any serious medical issues that have re-
stricted their participation. Finally, the follow-up surveys
and the health diary will ask patients to self-report any
adverse events they may have experienced during the
course of the trial. All SAEs will be reported to the ap-
proving HREC’s.
Future use of data
Information collected for this study may be used in fu-
ture projects or submitted to a public database so that
other researchers can access it and use it. At this stage,
it is not known what these other projects will involve.
We will seek ethical approval before using the informa-
tion in these future projects, and any identifying infor-
mation will be removed. All participants (general
practices, GPs and patients), will be advised of the po-
tential for future use of their de-identified data in the
Patient Information Statement and Consent Forms.
Discussion
Given knee OA is one of the most prevalent and disab-
ling chronic diseases, even small reductions in ineffective
practices with small improvements in care may lead to
marked cost savings and reductions in the individual
and societal burden of the disease. If the PARTNER
intervention rationale is correct and implementation is
successful, the results will have major significance for
Australia with potential implications internationally, in-
cluding potential relevance to low- and middle-income
settings in the context of remotely-delivered care. The
intervention is intentionally complex and targets both
GPs and patients. By improving the capacity of GPs to
offer their patients support for behavioural change
through the CST, we hope to ensure uptake and main-
tenance of exercise and weight loss and better satisfac-
tion with the care they are provided. We also hope to
improve access to high-quality self-management support
and behavioural counselling for patients, and by so
doing improve adherence to effective conservative non-
drug treatment including exercise and weight loss, thus
reducing the OA burden.
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We have clear intentions for subsequent imple-
mentation by planning to ensure the intervention is
acceptable, feasible, aligned with current Australian
models of care and to assess its cost-effectiveness.
We will assess the barriers and facilitators to more
widespread implementation and work closely with
stakeholders including consumers, government and
insurers to ensure policy recommendations stem
from this work if found to be effective and cost-
effective.
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